Регуляция секреции глюкагона гормонами инкретинового ряда у лиц с факторами риска сахарного диабета 2-го типа
Аннотация
Об авторах
Е А ШестаковаА В Ильин
А Д Деев
М В Шестакова
И И Дедов
Список литературы
1. Knop F.K., Vilsboll T., Madsbad S., Holst J.J., Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007; 50: 797-805.
2. Visboll T., Krarup T., Madsbad S., Holst J.J. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111-1119.
3. Lund A., Vilsboll T., Bagger J.I., Holst J.J., Knop F.K. The separate and combined impact of the intestinal hormones, GIP, GLP-1 and GLP-2, on glucagon secretion in type 2 diabetes. Am J Phys Endocrinol Metabol 2011; 300: E1038-E1046.
4. Hare K.J., Knop F.K., Asmar M., Madsbad S., Deacon C.F., Holst J.J., Vilsboll T. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metabol 2009; 94: 4679-4687.
5. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2-го типа. - М: Дипак, 2010.
6. Shah P., Vella A., Basu A., Basu R., Schwenk W.F., Rizza R.A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metabol 2000; 85: 4053-4059.
7. Holst J.J. On the physiology of GIP and GLP-1. Horm Metabol Res 2004; 36: 747-754.
8. Meier J.J., Gallwitz B., Siepmann N. et al. Gastric inhibitory poly- peptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003; 46:798-801.
9. Christensen M., Vedtofte L., Holst J.J., Vilsbøll T., Knop F.K. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60(12):3103-3109.
10. Meier J.J., Nauck M.A., Pott A., Heinze K., Goetze O., Bulut K., Schmidt W.E., Gallwitz B., Holst J.J. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006; 130:44-54.
11. Sorensen L.B., Flint A., Raben A., Hartmann B., Holst J.J., Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metabol Dis 2003; 27: 450-456.
Для цитирования:
Шестакова Е.А., Ильин А.В., Деев А.Д., Шестакова М.В., Дедов И.И. Регуляция секреции глюкагона гормонами инкретинового ряда у лиц с факторами риска сахарного диабета 2-го типа. Проблемы Эндокринологии. 2014;60(1):32-35. https://doi.org/10.14341/probl201460132-35
For citation:
Shestakova E.A., Ilyin A.V., Deev A.D., Shestakova M.V., Dedov I.I. Regulation of glucagon secretion by incretin-like hormone family in the patients at risk of developing type 2 diabetes mellitus. Problems of Endocrinology. 2014;60(1):32-35. (In Russ.) https://doi.org/10.14341/probl201460132-35